Pharma Deal Structure Explorer

LEO Pharma / dersimelagon — $435M illustrative milestone breakdown

Milestone Sliders

Presets

Actions

Assumptions & Sources

Reuters (2026-08-18): "LEO Pharma buys worldwide dersimelagon rights for up to $435 million" — reut.rs/4hAN0PS
Only the aggregate "up to $435M" figure is public; milestone splits are illustrative defaults based on typical dermatology asset structures.
Default split: Upfront ~15%, Phase 1 ~6%, Phase 2 ~9%, Phase 3 ~16%, Regulatory ~20%, Commercial ~35%.
Sliders proportionally clamp when sum exceeds $435M; last change can be replayed.
State persists in localStorage; Reset clears storage and restores LEO defaults.

Enjoy this tool? Build your own with Super